glp 1 lawsuit update Novo Nordisk A/S (NVO) Securities Class Action Judicial Panel Authorizes New GLP-1

Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders

GLP-1 is a naturally occurring incretin hormone released by the intestines in response to food intake

The microdose path is a differentiator for side-effect-sensitive patients

It is also worth noting that oxalates found in many commonly consumed foods are histamine liberators, meaning they can trigger histamine release even in foods that are not themselves high in histamine

They can evaluate adherence, injection technique, lifestyle factors, concurrent medications, and whether dose optimisation or combination therapy is needed

Ro's patients can also message their care team any time to request that Ro transfer their prescription on their behalf